100 related articles for article (PubMed ID: 25417051)
1. In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach.
Dinger J; Meyer MR; Maurer HH
Arch Toxicol; 2016 Feb; 90(2):305-18. PubMed ID: 25417051
[TBL] [Abstract][Full Text] [Related]
2. Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse.
Dinger J; Meyer MR; Maurer HH
Toxicol Lett; 2014 Oct; 230(1):28-35. PubMed ID: 25111188
[TBL] [Abstract][Full Text] [Related]
3. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
[TBL] [Abstract][Full Text] [Related]
4. Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MS
Michely JA; Brandt SD; Meyer MR; Maurer HH
Anal Bioanal Chem; 2017 Feb; 409(6):1681-1695. PubMed ID: 27933361
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class.
Dinger J; Woods C; Brandt SD; Meyer MR; Maurer HH
Toxicol Lett; 2016 Jan; 241():82-94. PubMed ID: 26599973
[TBL] [Abstract][Full Text] [Related]
6. A sensitive and high-throughput LC-MS/MS method for inhibition assay of seven major cytochrome P450s in human liver microsomes using an in vitro cocktail of probe substrates.
Liu LY; Han YL; Zhu JH; Yu Q; Yang QJ; Lu J; Guo C
Biomed Chromatogr; 2015 Mar; 29(3):437-44. PubMed ID: 25098274
[TBL] [Abstract][Full Text] [Related]
7. 2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6.
Ewald AH; Maurer HH
Toxicol Lett; 2008 Dec; 183(1-3):52-7. PubMed ID: 18938231
[TBL] [Abstract][Full Text] [Related]
8. Metabolic interactions with piperazine-based 'party pill' drugs.
Antia U; Tingle MD; Russell BR
J Pharm Pharmacol; 2009 Jul; 61(7):877-82. PubMed ID: 19589229
[TBL] [Abstract][Full Text] [Related]
9. Screening of ten cytochrome P450 enzyme activities with 12 probe substrates in human liver microsomes using cocktail incubation and liquid chromatography-tandem mass spectrometry.
Kim HJ; Lee H; Ji HK; Lee T; Liu KH
Biopharm Drug Dispos; 2019 Apr; 40(3-4):101-111. PubMed ID: 30730576
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
Grimm SW; Dyroff MC
Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the inhibition risk of shikonin on cytochrome P450 via cocktail inhibition assay.
Tang S; Chen A; Zhou X; Zeng L; Liu M; Wang X
Toxicol Lett; 2017 Nov; 281():74-83. PubMed ID: 28941798
[TBL] [Abstract][Full Text] [Related]
12. Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs-Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps.
Wink CS; Meyer GM; Meyer MR; Maurer HH
Toxicol Lett; 2015 Nov; 238(3):39-44. PubMed ID: 26276083
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes.
Cho DY; Bae SH; Lee JK; Kim YW; Kim BT; Bae SK
Drug Metab Dispos; 2014 Jan; 42(1):33-9. PubMed ID: 24167220
[TBL] [Abstract][Full Text] [Related]
14. Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions.
Lee KS; Kim SK
J Appl Toxicol; 2013 Feb; 33(2):100-8. PubMed ID: 21915887
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive assay for nine major cytochrome P450 enzymes activities with 16 probe reactions on human liver microsomes by a single LC/MS/MS run to support reliable in vitro inhibitory drug-drug interaction evaluation.
Peng Y; Wu H; Zhang X; Zhang F; Qi H; Zhong Y; Wang Y; Sang H; Wang G; Sun J
Xenobiotica; 2015; 45(11):961-77. PubMed ID: 26007223
[TBL] [Abstract][Full Text] [Related]
16. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
[TBL] [Abstract][Full Text] [Related]
17. Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities.
Oganesian A; Shilling AD; Young-Sciame R; Tran J; Watanyar A; Azam F; Kao J; Leung L
Psychopharmacol Bull; 2009; 42(2):47-63. PubMed ID: 19629022
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MSn, and LC-HR-MS-MS.
Michely JA; Helfer AG; Brandt SD; Meyer MR; Maurer HH
Anal Bioanal Chem; 2015 Oct; 407(25):7831-42. PubMed ID: 26297461
[TBL] [Abstract][Full Text] [Related]
19. Designer drugs that are potent inhibitors of CYP2D6.
Pritzker D; Kanungo A; Kilicarslan T; Tyndale RF; Sellers EM
J Clin Psychopharmacol; 2002 Jun; 22(3):330-2. PubMed ID: 12006905
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
Mössner LD; Schmitz A; Theurillat R; Thormann W; Mevissen M
Am J Vet Res; 2011 Nov; 72(11):1505-13. PubMed ID: 22023129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
